Pharmacokinetics of Mitozolomide in Mice
Author Information
Author(s): C. Goddard, J.A. Slack, M.F.G. Stevens
Primary Institution: CRC Experimental Cancer Chemotherapy Research Group, Department of Pharmaceutical Sciences, Aston University
Hypothesis
Mitozolomide may be a stable pro-drug form of MCTIC and its pharmacokinetics differ from clinically used nitrosoureas.
Conclusion
Mitozolomide shows good systemic availability and relatively sustained plasma levels, which may be beneficial for therapeutic use.
Supporting Evidence
- Mitozolomide was rapidly absorbed with peak plasma levels reached within 15 minutes.
- The drug showed good systemic availability when administered orally and transdermally.
- Mitozolomide exhibited no apparent dose dependency over the tested range.
- The pharmacokinetics of mitozolomide differ significantly from those of nitrosoureas BCNU and CCNU.
Takeaway
Mitozolomide is a new cancer drug that works well in mice and stays in the body longer than some other similar drugs.
Methodology
The study involved dosing male BALB/c mice with mitozolomide via different routes and measuring plasma levels over time.
Limitations
The study was conducted only in mice, and results may not directly translate to humans.
Participant Demographics
Male BALB/c mice weighing approximately 25g.
Want to read the original?
Access the complete publication on the publisher's website